Dr. Murphy on the influence of genomic testing in prostate cancer
"For those people in the intervention arm who did get the assay, the doctors were more likely to prefer active treatment with surgery or radiation compared to the control group," says Adam B. Murphy, MD, MBA, MSCI.
In this video, Adam B. Murphy, MD, MBA, MSCI, highlights the background and notable findings from the study, “Impact of genomic testing on urologists’ treatment preference in favorable risk prostate cancer: A randomized trial,” for which he served as the senior author. Murphy is an assistant professor of urology at Northwestern University in Chicago, Illinois.
Video Transcript:
Could you describe the background for this study?
This was a study based off of clinical trial we did from 2016 to 2019. It was all in safety net hospitals. It was a unique trial in a few ways, because it was testing the clinical utility of the genomic prostate score, genomics assay. We wanted to see how it affected both patient and provider treatment choices and preferences. That's a first of its kind trial design, we think. The other thing that was unique about it was that it was taking place in safety net hospitals. University of Illinois in Chicago, Cook County Health and Jesse Brown VA. So, it was a pretty unique study in that way. It was a randomized control trial. We were providing level 1 evidence of what the impact of this this assay would be on providing treatment preferences. This comes in the backdrop of retrospective data saying that these assays helped providers increase their uptake of active surveillance. Because at the time, active surveillance was growing in popularity, it was not quite as arrived as it is now. People have real concerns about whether they should be doing active surveillance in African American men, so the other part of our study that's interesting is that it's about 70% Black patients enrolled in the population.
What were the notable findings from this study?
A couple of notable findings were that the assay did seem to increase urologists' preference for active treatment with surgery or radiation relative to active surveillance uptake. Overall, this study showed that there was increased active surveillance uptake across our whole study compared to what the general population of urologists were preferring. Patients definitely received active surveillance at a really high rate in this trial compared to the national average, which is about 44%. We were at about 80% for this study for active surveillance uptake. For those people in the intervention arm who did get the assay, the doctors were more likely to prefer active treatment with surgery or radiation compared to the control group.
This transcription has been edited for clarity.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Destigmatizing Urology: Dr. Amarasekera discusses sexual minorities in urology
January 26th 2022“Gay people have had this history of feeling like the health care system and the structures that are supposed to protect them haven't protected them and kept them safe,” says Channa Amarasekera, MD.
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC
April 5th 2024“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
